Gene therapy in ophthalmology has developed rapidly, and there has been a breakthrough in the treatment of Leber's hereditary optic neuropathy. After receiving an intravitreal injection of rAAV2-ND4, patients followed up over a certain time period showed a definite increase in visual acuity. Visual acuity testing is critical for assessing the efficacy of rAAV2-ND4 intravitreal injection.
语种：
外文
被引次数：
WOS：
PubmedID：
第一作者：
第一作者单位：[1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Ophthalmol,Wuhan,Hubei,Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Li Bin,Wu Chenmian.Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients[J].RETINAL GENE THERAPY: METHODS AND PROTOCOLS.2018,1715:305-311.doi:10.1007/978-1-4939-7522-8_22.
APA：
Li, Bin&Wu, Chenmian.(2018).Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients.RETINAL GENE THERAPY: METHODS AND PROTOCOLS,1715,
MLA：
Li, Bin,et al."Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients".RETINAL GENE THERAPY: METHODS AND PROTOCOLS 1715.(2018):305-311
